StockUS listing USHRMYNASDAQHealthcareQuality Compounder

Harmony Biosciences Holdings(HRMY) Stock Analysis | Healthcare

USD --+0.00%
Reward77High
Risk29Low
75%Data
Strong 18% profit margin · Revenue growing 12% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 1.91Bn
Reward Ratingⓘ77 High reward assessment · 75% data coverage
Top 10% of stocksView factors
Risk Ratingⓘ29 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on HRMY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Harmony Biosciences Holdings?

, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.

AI Brief Pro

The brief on Harmony Biosciences Holdings

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Harmony Biosciences Holdings?

, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.91B, and a P/E ratio of 10.8x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: High (77)
Company Information
SectorHealthcare
IndustryBiotechnology
P/E Ratio10.7914
Beta0.976
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
772,406 shares
$3.1M
0
3-6months
0
0
6-9months
0
0
9-12months
570,640 shares
$2.7M
0